A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
September 27, 2022
Primary Completion Date
January 28, 2023
Study Completion Date
January 28, 2023
Conditions
Healthy Volunteers
Interventions
DRUG
Cenobamate
200 mg Cenobamate Tablet
Trial Locations (1)
78217
Worldwide Clinical Trials, San Antonio
All Listed Sponsors
lead
SK Life Science, Inc.
INDUSTRY
NCT05572255 - A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally | Biotech Hunter | Biotech Hunter